These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 8250103)

  • 1. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease.
    Gazzinelli RT; Galvao LM; Krautz G; Lima PC; Cancado JR; Scharfstein J; Krettli AU
    Am J Trop Med Hyg; 1993 Nov; 49(5):625-35. PubMed ID: 8250103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens].
    Moretti E; Cervetta L; Basso B; Castro I; Santamarina N
    Bol Chil Parasitol; 1998; 53(1-2):3-9. PubMed ID: 9830716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a natural human antibody with anti-galactosyl(alpha 1-2)galactose specificity that is present at high titers in chronic Trypanosoma cruzi infection.
    Avila JL; Rojas M; Velazquez-Avila G
    Am J Trop Med Hyg; 1992 Oct; 47(4):413-21. PubMed ID: 1279994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi.
    Almeida IC; Ferguson MA; Schenkman S; Travassos LR
    Biochem J; 1994 Dec; 304 ( Pt 3)(Pt 3):793-802. PubMed ID: 7818483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPI-anchored glycoconjugates from Trypanosoma cruzi trypomastigotes are recognized by lytic anti-alpha-galactosyl antibodies isolated from patients with chronic Chagas' disease.
    Almeida IC; Ferguson MA; Schenkman S; Travassos LR
    Braz J Med Biol Res; 1994 Feb; 27(2):443-7. PubMed ID: 8081263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease.
    Guevara AG; Taibi A; Alava J; Guderian RH; Ouaissi A
    Trans R Soc Trop Med Hyg; 1995; 89(4):447-8. PubMed ID: 7570896
    [No Abstract]   [Full Text] [Related]  

  • 8. The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives.
    Krettli AU
    Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():142-51. PubMed ID: 19753469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivity of chagasic antigal antibodies with noninfected cells treated with Trypanosoma cruzi secreted/excreted antigens.
    Yokoyama-Yasunaka JK; Piazza RM; Umezawa ES; Stolf AM
    J Clin Lab Anal; 1998; 12(2):108-14. PubMed ID: 9524295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cysteine-dependent protease in Trypanosoma cruzi useful for the diagnosis of Chagas disease].
    Alberti Amador E; Fachado Carvajales A; Montalvo AM; Izquierdo Pérez LA; Fonte Galindo L
    Rev Cubana Med Trop; 1998; 50(1):75-81. PubMed ID: 9842273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
    Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
    Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of anti-B13 antibodies over time in a cohort of chronic infected by Trypanosoma cruzi. Its relationship with specific treatment and clinical status.
    Olivera V; Bizai ML; Arias E; Suasnabar S; Bottasso O; Marcipar I; Fabbro D
    Acta Trop; 2021 Jun; 218():105908. PubMed ID: 33789152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections.
    Leguizamón MS; Campetella O; Russomando G; Almiron M; Guillen I; Ganzález Cappa SM; Frasch AC
    J Infect Dis; 1994 Dec; 170(6):1570-4. PubMed ID: 7995998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study.
    Galvao LM; Nunes RM; Cançado JR; Brener Z; Krettli AU
    Trans R Soc Trop Med Hyg; 1993; 87(2):220-3. PubMed ID: 8337734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.
    Balouz V; Melli LJ; Volcovich R; Moscatelli G; Moroni S; González N; Ballering G; Bisio M; Ciocchini AE; Buscaglia CA; Altcheh J
    J Clin Microbiol; 2017 Dec; 55(12):3444-3453. PubMed ID: 28978686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and comparison of enzyme immunoassays for diagnosis of Chagas' disease using fixed forms of Trypanosoma cruzi (Epimastigotes, Amastigotes, and Trypomastigotes) and assessment of antigen stability for the three assays.
    Berrizbietia M; Ndao M; Gottschalk M; Aché A; Vásquez F; Lacouture S; Medina M; Ward BJ
    J Clin Microbiol; 2004 Apr; 42(4):1766-9. PubMed ID: 15071044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purified excreted-secreted antigens from Trypanosoma cruzi trypomastigotes as tools for diagnosis of Chagas' disease.
    Berrizbeitia M; Ndao M; Bubis J; Gottschalk M; Aché A; Lacouture S; Medina M; Ward BJ
    J Clin Microbiol; 2006 Feb; 44(2):291-6. PubMed ID: 16455872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease.
    Martins-Filho OA; Pereira ME; Carvalho JF; Cançado JR; Brener Z
    Clin Diagn Lab Immunol; 1995 Sep; 2(5):569-73. PubMed ID: 8548536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Field evaluation of four novel enzyme immunoassays for Chagas' disease in Venezuela blood banks: comparison of assays using fixed-epimastigotes, fixed-trypomastigotes or trypomastigote excreted-secreted antigens from two Trypanosoma cruzi strains.
    Berrizbeitia M; Ndao M; Bubis J; Gottschalk M; Aché A; Lacouture S; Medina M; Ward BJ
    Transfus Med; 2006 Dec; 16(6):419-31. PubMed ID: 17163873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoconjugates of Trypanosoma cruzi: a 74 kD antigen of trypomastigotes specifically reacts with lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease.
    Almeida IC; Krautz GM; Krettli AU; Travassos LR
    J Clin Lab Anal; 1993; 7(6):307-16. PubMed ID: 8277354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.